Inclusion Criteria:  Age 1-18 years. CKD patients stages 3 to 5 (on or not on dialysis). Baseline hemoglobin 9 - 12 g/dL. Subject should have adequate transferrin saturation (≥20%) and serum ferritin (≥100 ng/mL). Stable erythropoietin therapy for 8 weeks ( defined as a ≤25% change in prescribed dose, no change in the route of administration and no more than one missed or withheld dose).  Exclusion Criteria:  Subject scheduled for a living-related kidney transplant. Subject with uncontrolled hypertension. HIV positive patient. The patient with known hematologic disease or cause of anemia other than renal disease. Patient with a history of seizure disorder or received antiepileptic medication for a seizure disorder within 6 months prior to enrolment. Hyperparathyroidism (Intact parathyroid hormone more than 1500 pg/ml or biopsy proven marrow fibrosis). Major surgery within 12 weeks. Active inflammatory disease within 8 weeks of randomization requiring immunosuppressive therapy. Clinical evidence of malignancy. Blood transfusion within 8 weeks prior to initiation of therapy.